Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novanta (NOVT) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Novanta (NOVT) over the last 16 years, with Q3 2025 value amounting to $987000.0.

  • Novanta's Asset Writedowns and Impairment fell 3768.94% to $987000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 4989.7%. This contributed to the annual value of $8.8 million for FY2024, which is 1724.74% up from last year.
  • As of Q3 2025, Novanta's Asset Writedowns and Impairment stood at $987000.0, which was down 3768.94% from $933000.0 recorded in Q2 2025.
  • Novanta's 5-year Asset Writedowns and Impairment high stood at $4.3 million for Q2 2024, and its period low was $397000.0 during Q2 2022.
  • For the 5-year period, Novanta's Asset Writedowns and Impairment averaged around $1.3 million, with its median value being $1.0 million (2022).
  • In the last 5 years, Novanta's Asset Writedowns and Impairment surged by 42065.49% in 2023 and then plummeted by 7838.78% in 2025.
  • Over the past 5 years, Novanta's Asset Writedowns and Impairment (Quarter) stood at $440000.0 in 2021, then surged by 138.18% to $1.0 million in 2022, then decreased by 11.45% to $928000.0 in 2023, then soared by 57.11% to $1.5 million in 2024, then crashed by 32.3% to $987000.0 in 2025.
  • Its last three reported values are $987000.0 in Q3 2025, $933000.0 for Q2 2025, and $757000.0 during Q1 2025.